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Experimental endolymphatic 
hydrops under action of a 
type II nitric oxide synthase 
inhibitor: otoacoustic 
emissions evaluation and 
electrocochleography
   Summary
Claudio Marcio Yudi Ikino1, Roseli Saraiva 
Moreira Bittar2, Karina Midori Sato3, Newton 
Macuco Capella4
In experimental endolymphatic hydrops distortion-products 
otoacoustic emission (dpoae) amplitudes decrease and 
there is elevation on electrocochleographic thresholds. 
Some authors found type ii nitric oxide synthase (nos ii) 
expression in hydropic cochleas and they suggest nitric 
oxide (no) may be involved in endolymphatic hydrops 
pathogenesis. The aim of this study was to evaluate the action 
of a nos ii inhibitor on dpoae and electrocochleography 
in experimental endolymphatic hydrops. Material and 
methods: endolymphatic hydrops was induced in 16 guinea 
pigs by obliterating the endolymphatic duct and sac in the 
right ear. They were divided in two groups: eigth guinea pigs 
under the action of aminoguanidine, a nos ii inhibitor and 
eigth control guinea pigs. We compared dpoae amplitudes at 
geometric means of frequencies 1062, 2187, 4375 and 7000 
hz, compound action potential threshold at 1000, 2000, 4000 
and 6000 hz and summating potential to action potential 
(sp/ap) ratio between the groups during the postoperative 
observation period of 16 weeks. Results: there were no 
significant changes in the dpoae amplitudes and in the sp/ap 
ratio. The group that received aminoguanidine had a lower 
degree of threshold increase at 2000 (p<0.05) And 6000 hz 
(p<0.05) In 12th postoperative week and at 1000 (p<0.05), 
2000 (P<0.001), 4000 (P<0.001) And 6000 hz (p<0.001) At 
16th postoperative week. Conclusions: nos ii inhibitor 
decreased the electrocochleography threshold elevation on 
experimental endolymphatic hydrops.
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INTRODUCTION
The Discovery of molecular and biochemical mech-
anisms involved in the cochlear physiology has revolution-
ized concepts and opened new frontiers for research on 
this complex and fascinating theme. Within this context 
we have nitric oxide (NO), participant in a number of 
physiological and physiopathological processes in various 
systems, in the inner ear it acts in neurotransmission and 
bears a regulating action on the vascular tonus and on 
homeostasis and endolymph1,2.
NO is synthesized from L-arginine by a family of 
cytoplasm enzymes called nitric oxide synthetases (NOS). 
These enzymes have three distinct isophorms: type I, or 
neuronal (NOS I), type II or induced (NOS II), and type III 
or endothelia (NOS III). NOS I and III are constitutional, 
calcium-dependent and produce small amounts of NO3. 
NOS II has its production induced by different stimulus 
such as cytokines, ischemia, interferon or lipopolysaccha-
ride, it is calcium-dependent, it is not usually expressed 
in the cochlea and produces NO in great amounts, about 
100 to 1000 times more that NOS I and III2,4,5-7.
When produced in greater amounts and continu-
ously, NO has neurotoxic and citotoxic effects, moreover, 
the former is catalyzed by NOS II2,7-10. Studies in which NO 
donors are used, in other words, exogenous substances 
that release NO when metabolized, show that NO causes 
cell injury and loss of hair cells. Besides structural lesions, 
there are alterations in electrophysiological thresholds, 
endocochlear potential, auditory nerve action potential 
amplitude and cochlear microphone amplitude2,11.
In a research carried out in guinea pigs with ex-
perimental endolymphatic hydrops secondary to endo-
lymphatic sac and duct block, NOS II was detected in 
ganglionic cells, support cells, spiral ligament and stria 
vascularis. From then, it was thought that the cells were 
damaged by an increase in hydrostatic pressure that would 
release pro-inflammatory cytokines, thus stimulating NOS 
II synthesis and the excessive production of NO. 8  NO-
related morphological and electrophysiological alterations 
that occur in the cochlear present similarities with the 
cochlear alterations that appear in animal models with 
endolymphatic hydrops, described in previous studies, thus 
suggesting a possible relationship between them12.
As to hearing outcomes in experimental endolym-
phatic hydrops, we observed a progressive deterioration of 
hearing levels, initially in the lower frequencies, followed 
by the high frequencies, and finally in the intermediate fre-
quencies, very similar to the clinical outcome of Menière’s 
disease13-15. There is reduction in the amplitude of the 
distortion product otoacoustic emissions (DPOAE) which 
happen early on in the first weeks after the experimental 
induction of endolymphatic hydrops, even before the 
increase in thresholds detected by the compound hearing 
potential16-18.
Thus, in the endolymphatic hydrops experimental 
model in guinea pigs, there is cochlear lesion, progressive 
increase in electrophysiological threshold and drop in 
DPOAE amplitude, such alterations are interconnected. In 
this same animal model NOS II expression was found in the 
cochlea, and such isophorm is not normally found in the 
inner ear. Therefore, it is possible that the NO synthesized 
under the action of the NOSII may play a role in the origin 
of cochlear histopathological alterations, of compound 
auditory potential and DPOAE observed in these experi-
mental animals and the use of a NOS II inhibitor could 
potentially modify the outcome of such alterations. 
The goal of the present study was to assess the ac-
tion of a type II Nitric Oxide Synthase, aminoguanidine, 
in distortion product otoacoustic emissions and electroco-
chleography in experimental animals with experimental 
endolymphatic hydrops by obliteration of the endolym-
phatic sac and duct.
MATERIALS AND METHODS
This research project followed the ethical principles 
upheld by the Brazilian College of Animal Experimentation, 
and was approved by the Ethics Committee on the use of 
animals of the UFSC under protocol numbers 261/CEUA 
and 23080.035333/2003-63/UFSC and by the Ethics Com-
mittee for the Analysis of Research Projects of the Univer-
sity Hospital of the Medical School of the University of São 
Paulo (FMUSP) under protocol number 588/04.
This experimental, case-controlled study was car-
ried out in 16 albino animals (Cavia porcellus), of short 
hair, adult, from both genders, with initial weight of 350 
to 400g, with a positive Preyer test and normal otoscopy. 
All animals underwent surgery to induce experimental 
endolymphatic hydrops in the right ear, with endolym-
phatic sac and duct obliteration through an extradural 
approach via posterior fossa19, under intramuscular given 
anesthesia using a Xylazine (5 mg/kg) and ketamine (50 
mg/kg)20 solution.
The animals were randomly divided in two 
groups:
a) Group I (Study): comprises 8 animals that re-
ceived selective NOS II inhibitor, 98.5% oral aminogua-
nidine bicarbonate (Sigma-Aldrich, Steinheim, Germany), 
in the drinking water, diluted in a 1% concentration, in a 
volume that matched the 100 mg dose of aminoguanidine 
perkg of body weight per day21, daily, from the 3rd day 
to the 16th week of postoperative ad libitum.
b) Group II (Control): comprises 8 animals that 
received only water from the drinking fountain.
DPOAE and electrocochleography tests were carried 
out on the right ears of 16 experimental animals under 
anesthesia in the preop and in the 1st, 4th, 8th, 12th and 
16th week of postop. Each animal underwent DPOAE 
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measures followed by electrocochleography, always on 
the right ear. The animals were randomly selected for the 
exams and the examiner did not know to which group the 
animal belonged when he did the electrocochleography. 
The measures of DPOAE amplitudes were carried 
out in sound treated rooms, using the WelchAllyn GSI 
60 DPOAE device with 70DbSPL intensity and primary 
frequency relations 1 (f1) and 2 (f2) of 1.2 in the follow-
ing frequency geometric averages: 1062, 2187, 4375 and 
7000Hz. At the end of the experiment we calculated both 
the average and standard deviation of the distortion prod-
uct amplitudes for each frequency geometric average, for 
each moment assessed and for each group. 
The electrocochleography was carried out in a 
sound treated room, using an Amplaid MK 22 device, 
with the active transtympanic electrode in the right ear, 
subcutaneous reference electrode in the median occipital 
region and subcutaneous mass electrode in the median 
frontal region. The acoustic stimuli were provided by a 
shell-type headphone model TDH 498 placed at 5 cm 
from the right ear. The electrophysiological action poten-
tial was measured in the frequencies of 1000, 2000, 4000 
and 6000Hz with a logon type of stimulus, of alternate 
polarity starting at 120 dB SPL with 10 dBSPL decrements 
and the SP/AP ratio with the click-type stimulus at 120 
dBSPL of alternate polarity. At the end of the experiment 
we calculated the average and the standard deviation of 
the electrophysiological thresholds for each frequency, 
for each moment assessed and for each group. We also 
calculated the average and standard deviation of the SP/
AP (summation potential/action potential) ratio for each 
moment for both groups. 
In order to assess the results between the study 
group and the control group and the evolution along 
the period studied, we used the Double Factor Variance 
Analysis for repeated measures, complemented by the 
Bonferroni t test. The software used was GraphPad Prism 
4 for Windows, version 4.02. We adopted a significance 
level (p) of 5% (p<0.05), according to the standards used 
in biological studies. 
RESULTS
We did not observe statistically significant differ-
ences in the DPOAE amplitudes in the frequencies tested 
along the study, nor between study and control groups 
(Figures 1 to 4).
There was a statistically significant increase in the 
double factor Variance Analysis of the electrophysiological 
thresholds seen in the electrocochleography in the fol-
lowing frequencies: 1000Hz (p<0.001; F=19.37). 2000Hz 
(p<0.001; F=21.21). 4000Hz (p<0.001; F=11.70) and 6000Hz 
(p<0.001; F=13.36) in both the control and study groups 
along the study period, pointing towards a hearing loss 
development and success in the endolymphatic hydrops 
induction.
Figures 5 to 8 depict the measures of electrophysi-
ological thresholds, and compare the values between 
control and study group along the study period. Figure 9 
shows the SP/AP ratio behavior in the study and control 
group where there was no statistically significant difference 
among them and in their values along the study period.
Figure 1. DPOAE: average of the amplitude measures in the study and 
control groups ± the standard deviation in the geometric averages in 
the frequency of 1062Hz.
Figure 2. DPOAE: average of the amplitude measures in the study and 
control groups ± the standard deviation in the geometric averages in 
the frequency of 2187Hz.
Figure 3. DPOAE: average of the amplitude measures in the study and 
control groups ± the standard deviation in the geometric averages in 
the frequency of 4375Hz.
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Figure 4. DPOAE: average of the amplitude measures in the study and 
control groups ± the standard deviation in the geometric averages in 
the frequency of 7000Hz.
Figure 5. Electrocochleography: electrophysiological threshold values 
in average ± standard deviation in the study and control group in the 
frequency of 1000Hz. * p<0.05 (t=2.520) between the values of both 
the study and control group in the t test of Bonferroni.
Figure 6. Electrocochleography: electrophysiological threshold values 
in average ± standard deviation in the study and control group in the 
frequency of 2000Hz. * p<0.05 (t=4.535) between the values of both 
the study and control group in the t test of Bonferroni.
Figure 7. Electrocochleography: electrophysiological threshold values 
in average ± standard deviation in the study and control group in the 
frequency of 4000Hz. * p<0.001 (t=3.779) between the values of both 
the study and control group in the t test of  Bonferroni.
Figure 8. Electrocochleography: electrophysiological threshold val-
ues in average ± standard deviation in the study and control group 
in the frequency of 6000Hz. * p<0.05 (t=2.520); p<0.001 (t=4.787) 
between the values of both the study and control group in the t test 
of  Bonferroni.
Figure 9. Electrocochleography measured from the SP/AP ration in 
average ± the standard deviation in both the study and the control 
group.
155
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 72 (2) MARCH/APRIL 2006
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
DISCUSSION
The DPOAE amplitude measures did not show 
variations along the study in neither the control nor the 
study group. The sample size, together with the great in-
dividual variability may have had an impact there. In some 
studies, DPOAE amplitude in the endolymphatic hydrops 
experimental model shows a reduction already in the 1st 
week of postoperative time16,18 while others, as it happened 
in our experiment, showed variable results, even with an 
amplitude increase after the reduction period, however it 
did not reach preoperative values17,22. Also, the intensity 
of the primary frequencies used varies according to the 
authors, making it difficult to compare the results. On the 
other hand, the amplitude alterations, when detected, 
precede the electrophysiological threshold alterations16,17 
thus, there may be other mechanisms responsible for 
its origin, and NOS II would not play an important role. 
Okubo et al. (1997)18 showed that the DPOAE amplitudes 
in 4000 and 6000Hz showed a reduction after 1 to 2 weeks 
of postoperative time, which returned to their baseline 
preoperative values with the use of osmotic antidiuretic 
agent, isosorbide, thus suggesting the role of endolymph 
pressure and volume in the DPOAE alterations. In this 
same study the endocochlear potential also reduced in the 
first week of postop, however isosorbide brought about 
a greater reduction in its measures, not showing any ap-
parent relation to DPOAE18.
We have seen a progressive increase in electro-
physiological thresholds in the control group in all the 
frequencies along the study period, initially in 1000 Hz 
already in the first week of postop, and in the remain-
ing frequencies it started on the 8th week. Our findings 
are similar to those from other authors, confirming how 
adequate this animal is as an experimental model for en-
dolymphatic hydrops13,16,23-25. Thresholds were higher than 
preoperative measures, probably because we provided the 
acoustic stimuli through a head phone placed at 5cm from 
the ear while others used it at 1cm22,24,26 or fit the phone to 
the external auditory canal13. Even then, the hearing loss 
pattern and level seen were similar. As to preoperative 
values, our results agree with those from Andrews et al. 
(2000)26. We tried to place the earphone as close as pos-
sible to the ear; however, the size of the transtympanic 
electrode used did not let us go closer. 
In the study group there was an increase in elec-
trophysiological thresholds in the frequencies of 1000 
and 2000Hz in the first 4 weeks of postop, reaching the 
remaining frequencies on the 8th week, in a similar pat-
tern to that of the control group. However, starting on 
the 12th week the hearing loss progression was less in 
the study group, being significant in 2000 and 6000 Hz, 
including the measures in 1000 and 4000 Hz on the 16th 
week. Therefore, oral aminoguanidine was able to reduce 
the hearing loss caused by endolymphatic hydrops in 
experimental animals as of the12th week postoperative, 
but did not preclude its development.
Aminoguanidine is a selective NOS II inhibitor27. Its 
intraperitoneal use in the dose of 100 mg/kg/day reduced 
tissue lesions and the increase in electrophysiological 
thresholds in experimental animals that had their cochleas 
submitted to transitory ischemia by clamping the labyrin-
thine artery, thus proving that aminoguanidine does reach 
the cochlear tissue21. Studies utilizing oral aminoguanidine 
bicarbonate in doses varying from 80 to 200 mg/kg/day, 
showed that the drug is absorbed by the GI tract and acts 
inhibiting NOS II action, because it reduces the lesions 
produced in disease models in which its expression in-
crease had been proved, and also reducing the urinary 
excretion of nitrites and nitrates, pointing towards a lower 
NO production. We believe that in our study aminogua-
nidine inhibited NOS II and, as we observed a reduction 
in the electrophysiological thresholds, we suggest that 
NO catalyzed by this enzyme plays a role in the patho-
genesis of endolymphatic hydrops. Michel et al. (2000)8 
and Watanabe et al. (2001)10 showed that there is NOS II 
expression in the cochlea of experimental animals with 
hydrops, suggesting its participation in disease develop-
ment. When an inhibitor of this enzyme is used we were 
able to change the hearing loss development, and this 
has come to reinforce that assumption. Notwithstanding, 
in order to compare, we did not find in the literature the 
use of NOS II inhibitor, either per os or parenteral in any 
endolymphatic hydrops experimental model. 
Although we did see a lower level of hearing loss 
in the study group, there was an increase in electrophysi-
ological thresholds, therefore, aminoguanidine did not 
prevent endolymphatic hydrops development. The fact 
that we started aminoguanidine on the 3rd day of postop 
may have caused it, because then we allowed NOS II to 
produce NO in the first two days. Our decision for start-
ing aminoguanidine as of that date was due to a risk of 
local infection, because the surgery used to cause endo-
lymphatic hydrops involved the dura mater, the occipital 
bone and the internal ear. Since NOS II participates in the 
inespecific cell mechanisms for defense and inflammation4 
, we decided to wait 2 days, thus allowing healing of the 
surgical wound. We do not know for sure when NOS II 
is synthesized, since Michel et al. (2000)8 showed this en-
zyme present in experimental animals at 3 weeks of the 
hydrops induction by a block in both the endolymphatic 
duct and sac, while Watanabe et al. (2001)10 showed NOS 
II expression already at 1 day of postop. In this last model, 
the authors used antigen injection in the endolymphatic 
sac to cause hydrops and we do not know if NOS II ex-
pression occurs at the same time in these two different 
induction models. In guinea pigs in which we produce 
cochlear lesions, either by LPS or by gentamicin, NOS II 
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is responsible for NO synthesis 48 hours after inoculating 
these toxic agents29. Another possibility is the use of oral 
aminoguanidine in the maximum dose of 100 mg/kg/day 
that may not have reached enough concentration for to-
tal NOS II inhibition. Oral use proved to be effective in 
other disease models in doses varying between 80 and 
200 mg/kg/day and in the dose of 100 mg/kg/day - that 
we used, in experimental animals exposed to cochlear 
ischemia, however via intraperitonium21,28. We are not 
certain whether this dosage was enough in endolymphatic 
hydrops, since we did not find other experiments that 
used it in this disease model. Our method did no include 
drug ingestion control that may have varied, as well as its 
serum level maintenance; notwithstanding, we observed 
that most animals, during the study period, drank all or 
almost all the drinking fountain water. And finally, there 
is the possibility that endolymphatic hydrops be of mul-
tifactorial pathogeny. Thus, aminoguanidine would not 
prevent hydrops onset, as we saw in our experiment in 
a significant way as of the 12th week. The mechanical 
obstruction of the endolymphatic sac and duct19,30 in ex-
perimental animals promotes endolymphatic hydrops with 
endolymphatic space distention already on the 1st day. In 
this model there is an increase in endolymph pressure in 
comparison to the perilymph after the 2nd week 26 which 
may cause hearing loss induced by the mechanical action 
or by cell lesion. The use of diuretics, such as glycerol25, 
is capable of reducing electrophysiological thresholds 
increase, but it also does not prevent the disease onset, 
suggesting that the increase in endolymphatic pressure 
does play a role, but it is not the only factor involved. In 
order to reinforce this aspect, studies that promote the 
increase in endolymphatic pressure through a catheter 
positioned within the endolymphatic duct, assessing the 
endolymphatic pressure factor alone caused hearing loss, 
initially on the high frequencies, and later on reaching 
the lower frequencies. Now, in the hydrops caused by 
endolymphatic duct and sac block, the lower frequencies 
hearing loss is the first to occurr24. These aforementioned 
alterations may be responsible or may happen together 
with NOS II expression, with NO production damaging 
hair cells and also the marginal cells of the stria vascularis 
and over activate the ON/GMPc via with consequent co-
chlear microcirculation dysfunction and greater glutamate 
release. The latter would block neural transmission through 
N-metil-D-aspartato receptors2,7,8,10,29. Aminoguanidine was 
probably capable of mitigating these lesions. 
We did not find any difference as far as the SP/
AP ration is concerned in the control group, like other 
authors14,23 who also used the active lead in the base of 
the cochlea. Aminoguanidine did not change this find-
ing. The mechanisms responsible for hearing alterations 
in experimental endolymphatic hydrops are various and 
not yet fully understood. NO comes up as one more ele-
ment involved in the disease genesis, and new studies to 
clarify its role, as well the interaction with the other factors 
presented in the literature are necessary. A better under-
standing of the endolymphatic hydrops physiopathology 
is the basis to develop new therapeutic approaches for 
the Menière Disease. 
CONCLUSIONS
We have concluded that aminoguanidine, NOS II 
inhibitor, caused a milder increase in the electrophysiology 
thresholds of experimental animals, and did not change 
the SP/AP ratio measured at the base of the cochlea; and 
also did not change DPOAE amplitudes along the 16 
weeks of the study.
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